The multiple myeloma research consortium announces initiation of first four-drug combination study to treat newly diagnosed multiple myeloma patients
August 21st, 2008 by 
admin The Multiple Myeloma Research Consortium (MMRC) declared the institution of a four-drug compounding think with REVLIMID® (lenalidomide), VELCADE® (bortezomib) for Injection, DOXIL® (doxorubicin HCl liposome injection) and Hexadrol for the communication of binary myeloma in patients who are previously untreated. (Source: Lymphoma / Leukemia News From Medical News Today)
Tags: ATM, Initiation, leukemia, Lim, Research Co
Posted in Cancer | 